US Patent

US9669019 — Sublingual apomorphine

Method of Use · Assigned to Sunovion Pharmaceuticals Inc · Expires 2030-06-11 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects sublingual formulations of apomorphine in unit dosage form, specifically mucoadhesive films containing a pH neutralizing agent and apomorphine particles.

USPTO Abstract

Disclosed are sublingual formulations of apomorphine in unit dosage form formulated for sublingual administration, where the unit dosage form is a mucoadhesive film containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine, and where the mucoadhesive film is formed by the steps of: (i) combining a film-forming mucoadhesive polymer, apomorphine particles comprising an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form a first film comprising the apomorphine particles, where the steps further include contacting or impregnating the first film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2825 apomorphine-hydrochloride
U-2825 apomorphine-hydrochloride
U-2825 apomorphine-hydrochloride
U-2825 apomorphine-hydrochloride
U-2825 apomorphine-hydrochloride

Patent Metadata

Patent number
US9669019
Jurisdiction
US
Classification
Method of Use
Expires
2030-06-11
Drug substance claim
No
Drug product claim
Yes
Assignee
Sunovion Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.